8-K: Current report filing
Published on July 13, 2017
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report: May 9, 2017
VISUALANT, INCORPORATED
(Exact name of Registrant as specified in its charter)
|
Nevada |
000-30262 |
90-0273142 |
|
(State or jurisdiction of incorporation) |
(Commission File No.) |
(IRS Employer Identification No.) |
500 Union Street, Suite 810
Seattle, Washington 98101
(206) 903-1351
(Address of Registrant’s principal executive office and telephone number)
Section 8 – Other Events
Item 8.01 Other Events.
Issuance of Eleventh Patent on its ChromaID™ technology
On May 9, 2017, Visualant, Incorporated (the “Company”), an emerging leader in next-generation optical sensor technology, announced that it had received its eleventh patent relating to its ChromaID™ technology.
The Company’s recently announced Joint Development Agreement with Biomedx, which is focused on the properties of human skin, falls squarely within the scope of the newly issued patent. That agreement provides for the use of ChromaID to analyze collagen and elastin as an aid in plastic reconstructive and cosmetic surgery.
The patent, issued by the United States Patent and Trademark Office as US Patent No. 9,625,371 B2, is entitled “Method, Apparatus, and Article to Facilitate Evaluation of Substances Using Electromagnetic Energy.”
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits –
|
Exhibit No. |
Description |
|
|
|
99.1 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Registrant: VISUALANT, INCORPORATED |
|
|
|
|
|
|
|
By: |
/s/ Ronald P. Erickson |
|
|
|
Ronald P. Erickson CEO |
July 13, 2017